Eczema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have had chronic atopic dermatitis (eczema) for at least 1 year before the study screening visit
- People aged 12 years or older at the time of joining the study
- People who have been diagnosed with moderate-to-severe atopic dermatitis by a certified skin specialist (dermatologist), and whose doctor has independently decided to prescribe abrocitinib as part of their normal care
- People who have already tried at least one, but no more than two, approved biologic treatments for moderate-to-severe atopic dermatitis, and either those treatments did not work well enough or they could not tolerate them
- People (or their legal representative) who have signed and dated a consent form after being fully informed about the study; for teenagers, agreement from the young person and their parent(s) or guardian(s) is required in line with local rules
- People who, in their doctor's opinion, are willing and able to attend regular clinic visits and complete patient questionnaires as required
Who may not be able to join:
- People who currently have other active inflammatory skin conditions (such as psoriasis, seborrheic dermatitis, or lupus affecting the skin) that could interfere with assessing their atopic dermatitis or response to treatment
- People who have previously been treated with abrocitinib or any other oral or systemic JAK inhibitor medication
- Staff members at the study sites, Pfizer employees directly involved in running the study, or close family members of those individuals
- People whose eligibility has not been formally reviewed and confirmed by an appropriate member of the study team before enrolment (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Phone: 1-800-718-1021
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of patients achieving EASI-75 improvement from baseline at Week 16 after index date; Percentage of patients achieving ≥ 4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS) collected daily all through the study from baseline at Week 2 by e-diary assessment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.